Switch‐over from Pharmalgen to Alutard Bee and Wasp venom in the UK

Nasser, Shuaib; Whyte, Andy; Durham, Stephen R.; Krishna, Mamidipudi Thirumala

doi:10.1111/cea.13529

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nassar and colleagues describe how to change patients to the Alutard SQ Bee and Wasp Venom products. 28 These have the advantage of having four different dilutions for updosing but they are not compatible for a rush or ultra-rush updoing strategy. There are alternative products that Erlewyn-Lajeunesse and colleagues have highlighted.…”

Section: Anaphylaxismentioning

confidence: 99%

See 1 more Smart Citation

Developments allergy in 2019 through the eyes of Clinical and Experimental Allergy, Part II clinical allergy

Roberts

Almqvist

Boyle

et al. 2020

Clin Experimental Allergy

View full text Add to dashboard Cite

In the second of two linked articles, we describe the development in clinical as described by Clinical & Experimental Allergy and other journals in 2019. Epidemiology, clinical allergy, asthma and rhinitis are all covered. In this article, we described the development in the field of allergy as described by Clinical and Experimental Allergy in 2019. Epidemiology, clinical allergy, asthma and rhinitis are all covered.

show abstract

Section: Anaphylaxismentioning

confidence: 99%

“…The supply of Pharmalgen for bee and wasp venom testing stopped in 2019. Nassar and colleagues describe how to change patients to the Alutard SQ Bee and Wasp Venom products 28 . These have the advantage of having four different dilutions for updosing but they are not compatible for a rush or ultra‐rush updoing strategy.…”

Section: Clinical Allergymentioning

confidence: 99%

Developments allergy in 2019 through the eyes of Clinical and Experimental Allergy, Part II clinical allergy

Roberts

Almqvist

Boyle

et al. 2020

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…The presence of an aluminium adjuvant in Alutard SQ means that it cannot be used for intradermal diagnostic testing, or for rush and ultrarush up dosing regimens, where aqueous extracts should be used for these purposes. 1 Ultrarush protocols induce tolerance over two-to three-day hospital admission. They are useful when protection is required as a matter of urgency, or there are circumstances that would preclude conventional weekly visits for up dosing.…”

mentioning

confidence: 99%